Toxicity antagonists in head and neck cancer

Seminars in Radiation Oncology

Volumn 8, Issue 4, 1998, Pages 282-291

  Trotti, A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; FATTY ACID; GRANULOCYTE COLONY STIMULATING FACTOR; KERATINOCYTE GROWTH FACTOR; LISOFYLLINE; MISOPROSTOL; PENTOXIFYLLINE; PILOCARPINE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ACUTE TOXICITY; CANCER RADIOTHERAPY; CHRONIC TONSILLITIS; DRUG EFFECT; HEAD CANCER; HUMAN; HUMAN TISSUE; MOLECULAR DYNAMICS; NECK CANCER; PRIORITY JOURNAL; REVIEW; TISSUE REACTION; TREATMENT PLANNING;

EID: 0031705406     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(98)80026-X     Document Type: Article

References (85)

1. Trotti A Toxicity antagonists in cancer therapy Curr Opin Oncol 9 1997 569 578
2. National Cancer Institute: Cancer Therapy Evaluation Program. Bethesda, MD. Available at: http://ctep.info.nih.gov. Accessed July, 1998.
3. Mustoe TA Porras-Reyes BH Modulation of wound healing response in chronic irradiated tissues Clin Plast Surg 20 1993 465 472
4. Rubin P Johnston C Williams J A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis Int J Radiat Oncol Biol Phys 33 1995 99 100
5. Martin M Lefaix J-L Pinton P Temporal modulation of TGF-beta-1 and beta-actin gene expression in pig skin and muscular fibrosis after ionizing radiation Radiat Res 134 1993 63 70
6. Randall K Coggle JE Long-term expression of transforming growth factor TGF beta 1 in mouse skin after localized beta-irradiation Int J Radiat Oncol Biol Phys 70 1996 351 601
7. Anscher MS Kong FM Murase T Short communication: Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ Br J Radiolo 68 1995 331 333
8. Wu L Siddiqui A Morris DE Transforming growth factor B3 (TGFB3) accelerates wound healing without alteration of scar prominence Arch Surg 132 1997 753 760
9. Bernstein EF Harisiadis L Salomon G Transforming growth factor-β improves healing of radiation-impaired wounds Soc Invest Dermatol 97 1991 430 434
10. Moreland LW Baumgartner SW Schiff MH Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc Fusion protein N Engl J Med 337 1997 141 147
11. Coleman N Bump E Kramer R Chemical modifiers of cancer treatment J clin Oncol 6 1988 709 733
12. Schuchter LM Luginbuhl WE The current status of toxicity protectants in cancer therapy Semin Oncol 19 1992 742
13. Schuchter LM Current role of protective agents in cancer treatment Oncology 11 1991 505 516
14. Klatersky J Supportive care in cancer Curr Opin Oncol 9 1997 313
15. Cox JD Stetz J Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
16. Ang KK Thames HD Peters LJ Altered fractionation schedules Principles and Pract Radiat Oncol 3 1997 119 142
17. Cox JD Pajak TF Marcial VA Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts Cancer 69 1992 2744 2748
18. Thames HD Bentzen SM Turesson I Time-dose factors in radiotherapy: A review of the human data Radiother Oncol 19 1990 219 235
19. Ang KK Peters LJ Weber RS Concomitant boost radiotherapy schedules in the treatment of carcinomas of the oropharynx and nasopharynx Int J Radiat Oncol Biol Phys 19 1990 1339 1345
20. Kaanders JHAM Dan Daal WAJ Hoogenraad WJ Accelerated fractionation radiotherapy for laryngeal cancer, acute and late toxicity Int J Radiat Oncol Biol Phys 24 1992 497 503
21. Wendt CD Peters LJ Ang KK Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx Int J Radiat Oncol Biol Phys 17 1989 1057 1062
22. Parsons JT Mendenhall WM Cassisi NJ Hyperfractionation for head and neck cancer Int J Radiat Oncol Biol Phys 14 1988 649 658
23. Horiot JC Le Fur R N'Guyen T Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Radiother Oncol 25 1992 231 241
24. Lamb DS Spry NA Gray AJ Accelerated fractionation radiotherapy for advanced head and neck cancer Radiother Oncol 18 1990 107 116
25. Peracchia G Alti C Radiotherapy with thrice-a-day fractionation in a short overall time: Clinical experiences Int J Radiat Oncol Biol Phys 7 1981 99 104
26. Saunders MI Dische S Grosch EJ Experience with CHART Int J Radiat Oncol Biol Phys 21 1991 871 878
27. Maciejewski B Skladowski K Pilecki B Randomized clinical trial on accelerated 7 days per week fraction in radiotherapy for head and neck cancer: Preliminary report on acute toxicity Radiother Oncol 40 1996 137 145
28. (abstract) Adelstein DJ Saxton JP Lavertu P Concurrent radiation and chemotherapy (CT) versus (vs) radiotherapy (RT) alone in resectable stage III and IV squamous cell head and neck cancer (SCHNG): A phase III randomized trial Proc Am Soc Clin Oncol 15 1996 26
29. Brizel D Albers M Fisher S Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 338 1998 1798 1804
30. Wendt TG Grabenbauer GG Rodel CM Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study J Clin Oncol 16 1998 1318 1324
31. Taylor SG Murthy AK Vannetzel JM Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer J Clin Oncol 12 1994 385 395
32. Browman GP Levine MN Hodson DI The HRNQ (Head and Neck Radiotherapy Questionnaire): A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer J Clin Oncol 11 1993 863 872
33. Browman GP Cripps C Hodson DI Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer J Clin Oncol 12 1994 2648 2653
34. Eschwege F Sancho-Garnier H Gerard JP Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: Experience of the European Organization for Research and Treatment of Cancer NCI Monographs No. 6 1988 275 278
35. Adelstein DJ Saxton JP Lavertu P A phase-III randomized trial comparing cocurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results Head Neck 1997 567 575
36. Al-Sarraf M LeBlanc M Shanker Giri PG Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 J Clin Oncol 16 1998 1310 1317
37. Ganser A Karthaus M Clinical use of hematopoietic growth factors Curr Opin Oncol 8 1996 265 269
38. Trillet-Lenoir V Green J Manegold C Recombinant granulocyte colony-stimulating factor reduces the infectious Eur J Cancer 29A 1993 319 324
39. Gabrilove J Jakubowski A Scher H Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium N Engl J Med 318 1988 1414 1422
40. Crawford J Ozer H Stoller R Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 1991 164 170
41. Werner S Peters KG Longaker MT Large induction of keratinocyte growth factor expression in the dermis during wound healing Proc Natl Acad Sci U S A 89 1992 6896 6900
42. Marchese C Rubin J Ron D Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: Differentiation response distinguishes KGF from EGF family J Cell Physiol 144 1990 326 332
43. Housley RM Morris CF Boyle B Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract J Clin Invest 94 1994 1764 1777
44. a. Ning S Shui C Khan W Effects of keratinocyte growth factor on the proliferation of human squamous cell carcinoma lines in vitro and in vivo Int J Radiat Oncol Biol Phys 40 1998 177 187
45. Absher M Baldor L Kelly J A rapid colorimetric bioassay for transforming growth factor-(TGF-β) using a microwell plate reader J Immunol Meth 138 1991 301 303g
46. Sonis ST Lindquist I Van Vugt A Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3 Cancer Res 54 1994 1135 1138
47. Milas L Hanson WR Eicosanoids and radiation Eur J Cancer 31A 1995 1580 1585
48. Hanson QR Marks JE Reddy SP Protection from radiation-induced oral mucositis by misoprostol prostaglandin E1 analog: A placebo controlled double blind clinical trial Am J Therap 2 1995 1 8
49. Clift RA Bianco JA Appelbaum FR A randomized controlled trial of pentoxifylline for the prevention of regimenrelated toxicities in patients undergoing allogeneic marrow transplantation Blood 82 1993 2025 2030
50. Stockschlader M Kalhs P Peters S Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients Bone Marrow Transplant 12 1993 357 362
51. van der Jagt RH Pari G McDiarmid SA Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation Bone Marrow Transplant 13 1994 203 207
52. Lee SH Slattery JT Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes Drug Metab Dispos 25 1997 1354 1358
53. Clarke E Rice GC Weeks RS Lisofylline inhibits transforming growth factor release and enhances trillineage hematopoietic recovery after 5-fluorouracil treatment in mice Cancer Res 56 1996 105 112
54. Rice G Rosen J Weeks R CT1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo Shock 1 1994 254 266
55. Cooper JS Fu K Late effects of radiation therapy in the head and neck region Int J Radiat Oncol Biol Phys 31 1995 1141 1164
56. Cox JD Pajak TF Marcial VA Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group protocol 83–13 Int J Radiat Oncol Biol Phys 20 1991 1191 1195
57. Peters IJ Ang KK Thames HD Accelerated fractionation in the radiation treatment of head and neck cancer: A critical comparison of different strategies Acta Oncol 27 1988 185
58. Jackson SM Weir LM Hay JH A randomized trial of accelerated versus conventional radiotherapy in head and neck cancer Radiother Oncol 43 1997 39 46
59. Fu K Pajak T Marcial V Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: Longterm follow-up results of RTOG 83-13 Int J Radiat Oncol Biol Phys 32 1995 577 588
60. Dische S Warburton MF Jones D The recording of morbidity related to radiotherapy Radiother Oncol 16 1989 103 108
61. Mollman JE Glover DJ Hogan WM Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721 Cancer 61 1988 2192 2195
62. Al-Sarraf M Fletcher WS Oishi N Cisplatin hydration with and without mannitol in refractory disseminated malignant melanoma: A Southwest Oncology Group Study Cancer Treat Rep 66 1982 31 35
63. Glover D Glick J Weiler C WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial J Clin Oncol 4 1986 584 588
64. Kemp G Rose P Lurain J Amifostine pretreatment for protection against cyclophosphamide-and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer J Clin Oncol 14 1996 2101 2112
65. (abstract 1152) Mchta M Larson MM Pharo L Phase II clinical trial of amifostine, cisplatin, vinblastine (ACV) and radiation therapy (RT) for unresectable stage III nonsmall cell lung cancer (NSCLC) Proc ASCO 14 1995 373
66. (abstract 1400) Buntzel J Kuttner K Russell L Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy Proc ASCO 16 1997 393a
67. th annual meeting Los Angeles, CA May 16–19, 1998
68. Johnson JT Ferretti GA Nethery WJ Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer N Engl J Med 329 1993 390 395
69. LeVeque F Fontanesi J Devi S Salivary gland sheltering using concurrent pilocarpine (PC) in irradiated head and neck cancer patients American Society of Clinical Oncology, 32nd Annual Meeting Philadelphia, PA May 18–21, 1996
70. Zimmerman RP Mark RJ Tran LM Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia Int J Radiat Oncol Biol Phys 37 1997 571 575
71. (abstract no. 1541) Lozada-Nur F Schoelch M Fu K Muscoplat: A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy Proc ASCO 1998 University of California at San Francisco San Francisco, CA 94143
72. Nagler R Marmary Y Fox PC Irradiation-induced damage to the salivary glands: The role of redox-active iron and copper Radiat Res 147 1997 468 475
73. Kim KH Kim JY Sung MW The effect of pilocarpine and atropine administration on radiation-induced injury of rat submandibular glands Acta Otolaryngol (Stockh) 111 1991 967 973
74. Horrobin DF Nutritional and medical importance of gammalinolenic acid Prog Lipid Res 31 1992 163 194
75. Cole AT Slater K Sokal M Elevated rectal leukotriene B4, thromboxane B2 and prostaglandin E2 levels in patients having pelvic radiotherapy Nigam S Hann KV Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 1993 Kluwer Academic Publishers Boston, MA 771 773
76. Hopewell JW Gerard JM Van Den Aardweg JMJ Amelioration of both early and late radiation-induced damage to pig skin by essential fatty acids Int J Radiat Oncol Biol Phys 30 1994 1119 1125
77. Scotia Pharmaceuticals, Sterling, UK, August 1988
78. Futran ND Trotti A Gwede C Pentoxifylline in the treatment of radiation-related soft tissue injury: Preliminary observations Laryngoscope 107 1997 391 395
79. Cornelison TL Naydich BO Hicks JE Trial of pentoxifylline in patients with functional disability caused by radiation-induced advanced regional fibrosis Society of Gynecologic Oncologists 28th Annual Meeting Phoenix, AZ March 22–26, 1997
80. Dion MW Hussey DH Doornbos Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis Int J Radiat Oncol Biol Phys 19 1990 401 407
81. Radiation Therapy Oncology Group: A randomized trial with pentoxifylline in the treatment of radiation-related soft tissue necrosis. Philadelphia, PA, RTOG 94-07
82. Delanian S Baillet F Huart J Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trial Radiother Oncol 32 1994 12 20
83. Perdereau B Campana F Vilcoq JR Superoxyde dismutase (Cu/Zn) en application cutanee dans le traitement des fibroses radio-induites Bull Cancer 81 1994 659 669
84. Benyahia B Campana F Perdereau B The effects of superoxide dismutase topical treatment on human skin radiofribrosis: a pathological study Breast 4 1995 1 7
85. Tsan MF Superoxide dismutase and pulmonary oxygen toxicity Proc Soc Exp Biol Med 214 1997 107 113